SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML
Choudhary G, Smith M, Pellagatti A, Bhagat T, Gordon S, Pandey S, Shah N, Aluri S, Booher R, Ramachandra M, Samson M, Pradhan K, Bowman T, Pillai M, Guha C, Wickrema A, Will B, Shastri A, Steidl U, Boultwood J, Starczynowski D, Verma A. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. Blood 2019, 134: 4224. DOI: 10.1182/blood-2019-124458.Peer-Reviewed Original ResearchToll-like receptorsAML cellsSF3B1 mutationsMDS/AML cellsInterleukin-1 Receptor-Associated KinaseMDS/AMLNF-kB activityInnate immune pathwaysInnate immune signalingNormal cellsDownstream oncogenic pathwaysLeukemic burdenCytokine releaseIRAK4 expressionNF-kBAML samplesImmune pathwaysSmall molecule inhibitorsNovartis PharmaceuticalsLeukemic cellsExon 6Mutation showTRAF6 activationAMLPharmacologic inhibition